NewAmsterdam Pharma (NAMS) Cash from Operations (2023 - 2026)

NewAmsterdam Pharma has disclosed Cash from Operations across 4 years of filings, most recently posting 30604000.0 for Q1 2026.

• Cash from Operations for Q1 2026 came in at 30604000.0, up 16.08% year-over-year; the trailing twelve-month figure through Mar 2026 was 141919000.0 (down 1.06% YoY), and the FY2025 annual result was 147783000.0, up 6.8% from the prior year.
• Cash from Operations came in at 30604000.0 for Q1 2026 at NewAmsterdam Pharma, up from 40875000.0 in the prior quarter.
• In the past five years, Cash from Operations ranged from a high of 12502000.0 in Q3 2024 to a low of 54602000.0 in Q1 2024.
• The 4-year median for Cash from Operations is 36468000.0 (2025), against an average of 36782230.77.
• Across the five-year window, Cash from Operations jumped 73.39% in 2024 and sank 162.11% in 2025, its largest moves.
• NewAmsterdam Pharma's Cash from Operations stood at 33074000.0 in 2023, then decreased by 13.32% to 37481000.0 in 2024, then slipped by 9.06% to 40875000.0 in 2025, then gained by 25.13% to 30604000.0 in 2026.
• The last three Cash from Operations figures came in at 30604000.0 (Q1 2026), 40875000.0 (Q4 2025), and 32769000.0 (Q3 2025), per Business Quant data.